Clinical Trial Update: The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) [Phase 2]

View source ↗

Summary

The WILLOW Phase 2 study evaluated M5049 in systemic lupus erythematosus with cutaneous lupus erythematosus (SCLE/DLE) and has completed with results posted on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• M5049

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2025-12-01